[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-385594-105":59,"doc-detail-385594-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","updates-in-gynecologic-care-for-individuals-with-lynch-syndrome","Updates in gynecologic care for individuals with lynch syndrome","","Review summarizing recent advances in identification and evidence-based management for individuals with Lynch syndrome, emphasizing endometrial and ovarian cancer prevention and early detection. Lynch syndrome is an autosomal dominant hereditary cancer condition driven by pathogenic variants in DNA mismatch repair genes (MLH1, MSH2, PMS2, MSH6) or EPCAM, with lifetime cancer risk varying by specific variant. The review highlights sentinel endometrial cancer, variant-specific ovarian risk uncertainty, earlier diagnosis, and the need for molecularly informed, targeted therapy approaches for mismatch repair–deficient tumors.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/updates-in-gynecologic-care-for-individuals-with-lynch-syndrome/385594/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/updates-in-gynecologic-care-for-individuals-with-lynch-syndrome/385594.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What causes Lynch syndrome and how does cancer risk vary between individuals?","Question",{"text":113,"@type":114},"Lynch syndrome results from autosomal dominant germline pathogenic variants in DNA mismatch repair genes (MLH1, MSH2, PMS2, MSH6) or EPCAM. Lifetime cancer risk ranges from about 10–90% and is influenced by the specific variant and associated cancer types.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is endometrial cancer especially important in Lynch syndrome for women?",{"text":118,"@type":114},"For women, endometrial cancer is the most common extracolonic cancer and is often the sentinel malignancy. The review notes variant-specific lifetime risks and highlights the need for clinicians to recognize Lynch-associated patterns early.",{"name":120,"@type":111,"acceptedAnswer":121},"How does Lynch syndrome affect ovarian cancer risk and diagnosis timing?",{"text":122,"@type":114},"The review states that some variants (notably involving MSH2 and MLH1) confer increased ovarian cancer lifetime risk, while updated evidence for MSH6 and PMS2 carriers does not show a definitive increased risk. Lynch-associated cancers are also diagnosed at earlier ages than in the general population.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},385594,1790491634,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","TYPE Review  \nPUBLISHED 01 March 2023  \nDOI 10.3389/fonc.2023.1127683  \nOPEN ACCESS  \nEDITED BY  \nToni T. Seppälä,  \nHelsinki University Central Hospital, Finland  \nREVIEWED BY  \nAnnika Auranen,  \nTampere University Hospital, Finland Emma J. Crosbie,  \nThe University of Manchester, United Kingdom  \n*CORRESPONDENCE Kari L. Ring  \n [KEL7J@hscmail. mcc.virginia.edu](KEL7J@hscmail. mcc.virginia.edu)  \nSPECIALTY SECTION  \nThis article was submitted to Cancer Genetics,  \na section of the journal Frontiers in Oncology  \nRECEIVED 19 December 2022  \nACCEPTED 16 February 2023  \nPUBLISHED 01 March 2023  \nCITATION  \nUnderkofler KA and Ring KL (2023) Updatesin gynecologic care for individuals  \nwith lynch syndrome.  \nFront. Oncol. 13:1127683 .  \ndoi: 10.3389/fonc.2023.1127683  \nCOPYRIGHT  \n© 2023 Underkofler and Ring. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nUpdates in gynecologic care for individuals with lynch syndrome  \nKaylee A. Underkofler and Kari L. Ring*  \nDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Virginia, Charlottesville, VA, United States  \nLynch syndrome is an autosomal dominant hereditary cancer syndrome caused by germline pathogenic variants (PVs) in DNA mismatch repair genes (MLH1, MSH2, PMS2, MSH6) or the EPCAM gene. It is estimated to affect 1 in 300 individuals and confers a lifetime risk of cancer of 10-90%, depending on the specific variant and type of cancer. Lynch syndrome is the most common cause of inherited colorectal cancer, but for women, endometrial cancer is more likely to be the sentinel cancer. There is also evidence that certain PVs causing Lynch syndrome confer an increased risk of ovarian cancer, while the risk of ovarian cancer in others is not well defined. Given this, it is essential for the practicing gynecologist and gynecologic oncologist to remain up to date on the latest techniques in identification and diagnosis of individuals with Lynch syndrome as well as evidence-based screening and risk reduction recommendations for those impacted. Furthermore, as the landscape of gynecologic cancer treatment shifts towards treatment based on molecular classification of tumors, knowledge of targeted therapies well-suited for mismatch repair deficient Lynch tumors will be crucial. The objective of this review is to highlight recent updates in the literature regarding identification and management of individuals with Lynch syndrome as it pertains to endometrial and ovarian cancers to allow gynecologic providers the opportunity to both prevent and identify Lynch-associated cancers earlier, thereby reducing the morbidity and mortality of the syndrome.  \nKEYWORDS  \nlynch syndrome, endometrial cancer, ovarian cancer, genetics, gynecology, gynecologic oncology  \n1 Introduction  \nLynch syndrome, first recognized in 1895, is a well-defined hereditary cancer syndrome that affects approximately 1 in 300 individuals in the general population (1, 2) . It is an autosomal dominant condition that is caused by pathogenic variants (PVs) in DNA mismatch repair (MMR) genes (MLH1, MSH2, PMS2, MSH6) or the EPCAM gene, which causes upstream promoter hypermethylation of MSH2 . The lifetime risk of developing cancer among those with Lynch syndrome is highly variable, ranging from 10-90%, and is now understood to be related to the specific pathogenic variant (PV) causing the disorder in an individual or family (3–5) . For example, those with a PV in MLH1 have a 71-90% lifetime risk of any Lynch cancer and a 35-90% lifetime risk of colorectal cancer whereas  \nFrontiers in Oncology 01 [frontiersin.or","cbCail8kQdcq3Y9Z","https://ap.wps.com/l/cbCail8kQdcq3Y9Z","pdf",604281,12,"English","# Introduction\n## Genetic basis and cancer risks\n## Importance for gynecologic providers\n# Key updates in identification and management (overview)\n## Screening and risk-reduction considerations\n## Molecular classification and targeted therapy relevance","[{\"question\":\"What causes Lynch syndrome and how does cancer risk vary between individuals?\",\"answer\":\"Lynch syndrome results from autosomal dominant germline pathogenic variants in DNA mismatch repair genes (MLH1, MSH2, PMS2, MSH6) or EPCAM. Lifetime cancer risk ranges from about 10–90% and is influenced by the specific variant and associated cancer types.\"},{\"question\":\"Why is endometrial cancer especially important in Lynch syndrome for women?\",\"answer\":\"For women, endometrial cancer is the most common extracolonic cancer and is often the sentinel malignancy. The review notes variant-specific lifetime risks and highlights the need for clinicians to recognize Lynch-associated patterns early.\"},{\"question\":\"How does Lynch syndrome affect ovarian cancer risk and diagnosis timing?\",\"answer\":\"The review states that some variants (notably involving MSH2 and MLH1) confer increased ovarian cancer lifetime risk, while updated evidence for MSH6 and PMS2 carriers does not show a definitive increased risk. Lynch-associated cancers are also diagnosed at earlier ages than in the general population.\"}]","Updates in gynecologic care for individuals with lynch syndrome | PDF",1790270140]